Definitive radiation therapy for invasive carcinoma of the vagina: impact of high-dose rate intracavitary brachytherapy

Nonaka, Tetsuo; Nakayama, Yuko; Mizoguchi, Nobutaka; Onose, Ryo; Kato, Hiroyuki; Nakayama, Hiroki

doi:10.1007/s10147-012-0379-7

Cited by 11 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seeger et al . [13] also reported favorable results for ISBT for primary carcinoma of the vagina and vulva, with no local recurrences of vaginal cancer with a median follow-up period of 27 months. In contrast, Nonaka et al .…”

Section: Discussionmentioning

confidence: 98%

Radiation therapy for primary vaginal carcinoma

Murakami¹,

Kasamatsu²,

Sumi³

et al. 2013

Journal of Radiation Research

View full text Add to dashboard Cite

Brachytherapy plays a significant role in the management of cervical cancer, but the clinical significance of brachytherapy in the management of vaginal cancer remains to be defined. Thus, a single institutional experience in the treatment of primary invasive vaginal carcinoma was reviewed to define the role of brachytherapy. We retrospectively reviewed the charts of 36 patients with primary vaginal carcinoma who received definitive radiotherapy between 1992 and 2010. The treatment modalities included high-dose-rate intracavitary brachytherapy alone (HDR-ICBT; two patients), external beam radiation therapy alone (EBRT; 14 patients), a combination of EBRT and HDR-ICBT (10 patients), or high-dose-rate interstitial brachytherapy (HDR-ISBT; 10 patients). The median follow-up was 35.2 months. The 2-year local control rate (LCR), disease-free survival (DFS), and overall survival (OS) were 68.8%, 55.3% and 73.9%, respectively. The 2-year LCR for Stage I, II, III and IV was 100%, 87.5%, 51.5% and 0%, respectively (P = 0.007). In subgroup analysis consisting only of T2–T3 disease, the use of HDR-ISBT showed marginal significance for favorable 5-year LCR (88.9% vs 46.9%, P = 0.064). One patient each developed Grade 2 proctitis, Grade 2 cystitis, and a vaginal ulcer. We conclude that brachytherapy can play a central role in radiation therapy for primary vaginal cancer. Combining EBRT and HDR-ISBT for T2–T3 disease resulted in good local control.

show abstract

Section: Discussionmentioning

confidence: 98%

Radiation therapy for primary vaginal carcinoma

Murakami¹,

Kasamatsu²,

Sumi³

et al. 2013

Journal of Radiation Research

View full text Add to dashboard Cite

show abstract

“…Radiotherapy is the mainstay of treatment for squamous cell carcinoma of the vagina [6,22,[48][49][50][51][52][53][54][55][56][57][58][59][60][61]86]. Therapy plans are individualized and involve combinations of BT and EBRT, which is essential to ensure the delivering of a curative dose to the clinical target volume [CTV], may be intracavitary or interstitial, depending on the extent, thickness, location and morphology of the tumor.…”

Section: Radiotherapymentioning

confidence: 99%

“…The standard treatment is radiotherapy, which utilizes external beam radiation [EBRT] and/or brachytherapy [BT] techniques [6,22,[48][49][50][51][52][53][54][55][56][57][58][59][60][61]. The addition of concurrent cisplatin-based chemotherapy has been recently incorporated in the treatment of this malignancy [62][63][64][65].…”

Section: Treatment Modalitiesmentioning

confidence: 99%

Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors

Gadducci

Fabrini

Lanfredini

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…From a total of 199 retrieved studies, 13 articles reporting data on 793 patients (median, 45; range, 26-138) met our inclusion criteria [7][8][9][10][11][12][13][14][15][16][17][18][19], as shown in Figure 1. The patients included in the analyzed studies were treated between 1959 and 2014, and the median follow-up for the whole population ranged from 27.6 to 90.0 months.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…All analyzed studies had a retrospective design. Tumor size was not reported in five studies [8,9,11,12,14]. In four studies, all treated patients had SCC VC [8,10,13,16], and in one study all treated patients had AC VC [9].…”

Section: Study Characteristicsmentioning

confidence: 99%

Definitive Radiotherapy in Invasive Vaginal Carcinoma: A Systematic Review

Guerri¹,

Perrone

Buwenge

et al. 2018

The Oncologist

View full text Add to dashboard Cite

Only retrospective studies, in a limited number, have been published on RT in VC in the past decade, with significant heterogeneity in terms of treatment characteristic and evaluation criteria. Clinical results were strongly influenced by tumor stage. Prospective randomized studies are needed to improve patients' outcomes, especially in advanced-stage disease.;23:1-10 IMPLICATIONS FOR PRACTICE: This study systematically reviews the recent literature on the role of definitive radiotherapy in the management of vaginal cancer and presents comprehensive data on clinical outcome and toxicity. The prognosis of patients is dismal, with a 5-year overall survival of approximately 50%. Early stage of the disease, small tumor size, previous hysterectomy, high pretreatment/treatment hemoglobin levels, and patients' age were correlated with a better clinical outcome. A brachytherapy boost should be delivered, especially in patients with higher-stage disease. The addition of concurrent weekly cisplatin should be considered in most patients, and transfusion should be used to maintain high hemoglobin levels.

show abstract

Definitive radiation therapy for invasive carcinoma of the vagina: impact of high-dose rate intracavitary brachytherapy

Abstract: Our results demonstrated that definitive RT with HDR-ICBT is effective for invasive carcinoma of the vagina, with acceptable toxicity.

Cited by 11 publications

References 23 publications

Radiation therapy for primary vaginal carcinoma

Radiation therapy for primary vaginal carcinoma

Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors

Definitive Radiotherapy in Invasive Vaginal Carcinoma: A Systematic Review

Contact Info

Product

Resources

About